In this article, experts forecast upcoming AI developments that will help shape a new commercial model, making 2021 the year when AI shifts from early exploration to broad adoption.
Ultimately, we should be excited about AI and its adoption in biopharma, but we should also stay sensible and focus our efforts where they’ll have the greatest impact.
The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.
In a HLTH session Tuesday, an executive at the pharma company offered an update on its efforts to become a digital and data powerhouse.